KFAS
PTGX icon

Keating Financial Advisory Services’s Protagonist Therapeutics PTGX Stock Holding History

Keating Financial Advisory Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.7K Buy
242
+18
+8% +$1.88K ﹤0.01% 845
2026
Q1 		$23.6K Buy
224
+222
+11,100% +$19.7K ﹤0.01% 834
2025
Q4 		$175 Buy
+2
New +$164 ﹤0.01% 2086

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Keating Financial Advisory Services's PTGX Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Protagonist Therapeutics (PTGX) stake by 8% in Q2 2026, buying an estimated $1.88K and bringing the position to 242 shares worth $29.7K. The position accounts for ﹤0.01% of the portfolio, ranked #845.

Keating Financial Advisory Services first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Keating Financial Advisory Services held 242 shares of Protagonist Therapeutics worth $29.7K as of Q2 2026.
  • Keating Financial Advisory Services bought 18 Protagonist Therapeutics shares in Q2 2026, an estimated $1.88K.
  • Protagonist Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #845 holding.
  • Keating Financial Advisory Services first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.